Prime Medicine, Inc. Common Stock (PRME)

Price$3.40

Value ScoreF

Growth ScoreD

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-19.72%

Price vs S&P 500 (4W)-0.87%

VGM Score37.05

Market Capitalization$641.19M

All Metrics

Book Value / Share (Quarterly)$0.42

P/TBV (Annual)2.14x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-16.96%

Cash Flow / Share (Quarterly)$-0.88

Price vs S&P 500 (YTD)-8.63%

Net Profit Margin (TTM)-4917.55%

EPS (TTM)$-1.26

10-Day Avg Trading Volume2.81M

EPS Excl Extra (TTM)$-1.26

EPS (Annual)$-1.35

ROI (Annual)-166.41%

Cash / Share (Quarterly)$0.75

Revenue Growth QoQ (YoY)-41.13%

ROA (Last FY)-58.69%

Revenue Growth TTM (YoY)4.89%

EBITD / Share (TTM)$-1.24

ROE (5Y Avg)-110.15%

Operating Margin (TTM)-5121.76%

Cash Flow / Share (Annual)$-0.93

P/B Ratio8.36x

P/B Ratio (Quarterly)8.19x

Net Income / Employee (Annual)$-1,377,700

EV / Revenue (TTM)143.06x

Net Interest Coverage (TTM)-82.30x

ROA (TTM)-60.97%

EPS Incl Extra (Annual)$-1.35

Current Ratio (Annual)4.84x

Quick Ratio (Quarterly)3.75x

3-Month Avg Trading Volume2.55M

52-Week Price Return181.75%

Revenue / Employee (TTM)$27,600

Tangible BV / Share (Quarterly)$1.99

P/S Ratio (Annual)138.43x

Asset Turnover (Annual)0.01x

52-Week High$6.94

EPS Excl Extra (Annual)$-1.35

CapEx CAGR (5Y)47.91%

26-Week Price Return-3.79%

Quick Ratio (Annual)4.76x

13-Week Price Return-18.95%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.80x

Enterprise Value$577.09M

Asset Turnover (TTM)0.01x

Revenue / Employee (Annual)$31,700

Pretax Margin (Annual)-4342.44%

Cash / Share (Annual)$0.98

3-Month Return Std Dev65.63%

Net Income / Employee (TTM)$-1,358,700

ROE (Last FY)-166.41%

Net Interest Coverage (Annual)-25.03x

EPS Basic Excl Extra (Annual)$-1.35

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.26

ROI (TTM)-188.82%

P/S Ratio (TTM)158.95x

Revenue / Share (Annual)$0.03

Tangible BV / Share (Annual)$3.25

Price vs S&P 500 (52W)153.54%

Year-to-Date Return2.31%

5-Day Price Return19.53%

EPS Normalized (Annual)$-1.35

ROA (5Y Avg)-63.07%

Net Profit Margin (Annual)-4342.44%

Month-to-Date Return0.14%

Cash Flow / Share (TTM)$-1.79

EBITD / Share (Annual)$-1.35

Operating Margin (Annual)-4498.06%

ROI (5Y Avg)-110.15%

EPS Basic Excl Extra (TTM)$-1.26

P/TBV (Quarterly)3.49x

P/B Ratio (Annual)5.18x

Pretax Margin (TTM)-4917.55%

Book Value / Share (Annual)$0.67

Price vs S&P 500 (13W)-28.70%

Beta2.30x

Revenue / Share (TTM)$0.02

ROE (TTM)-188.82%

52-Week Low$1.18

vGradeF

gGradeD

mGradeB

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.28est. -0.26

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.00

4.05

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
PRMEPrime Medicine, Inc. Common Stock	F	D	B	$3.40
AMGNAmgen Inc	C	C	C	$329.13
GILDGilead Sciences Inc	C	B	C	$131.10
ARGXargenx SE American Depositary Shares	D	A	C	$836.09
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$163.68
BIIBBiogen Inc. Common Stock	B	D	B	$192.23
BNTXBioNTech SE American Depositary Share	C	C	C	$91.70
MRNAModerna, Inc. Common Stock	C	B	B	$46.06
NBIXNeurocrine Biosciences Inc	C	B	B	$161.00
EXELExelixis Inc	C	B	B	$50.28
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$298.10

About

Prime Medicine Inc develops genetic therapies based on Prime Editing, a next-generation gene-editing technology designed to precisely correct genetic mutations and restore normal cellular function. The company targets rare and severe diseases with significant unmet medical needs across multiple therapeutic areas. Prime Editing's broader applicability compared to earlier gene-editing approaches positions the company to address a substantial market opportunity.